Navigation Links
Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
Date:2/4/2008

NEW YORK, Feb. 4 /PRNewswire/ -- There is a large and growing "treatment gap" between the number of patients worldwide who would benefit from an organ transplant and the number of organs available, a gap that is impacting transplant medicine markets, according to a new market research report from Kalorama Information, Organ Transplant Immunosuppressive Markets.

In the US, over 97,000 patients were on the United Network for Organ Sharing's list, while just 28,000 received a transplant. Other countries show similar gaps. This gap was first evident in 1998 and has increased every year.

Immunosuppressives, drugs which prevent the immune system from rejecting a new organ, may have become victims of their own success. Medicines such as Astella's Prograf and Roche's CellCept have reduced incidence of acute organ rejection and made transplantation a viable option in more cases, thus increased organ waiting lists. Kidney acute rejection rates alone decreased from 51% in 1996 to 13% eight years later as a result of these therapies. Over $5 billion worth of these drugs were sold in 2007.

"The pharmaceutical industry has created effective medications, and now the challenge is in the public policy arena," said Bruce Carlson, Publisher of Kalorama Information. "Awareness of the need for organ donation must be increased for the demand to be completely served. Volunteer efforts towards more organ donation have so far not been sufficient."

Despite the shortage, the study indicates that the marketplace for immunosuppressives will still grow at nearly five percent for the next five years due to a small increase in transplant operations and increased survival rates of patients who will require treatment for a longer period. But the study stresses that solving the donor shortage would lead to exponential growth in transplant medicine markets.

Organ Transplant Immunosuppressive Markets provides detailed statistics, market size and forecasts, trends and competitive analysis for kidney, liver, lung, heart and intestine transplants. This report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Organ-Transplant-Immunosuppressive-13995 27/

About Kalorama Information

Kalorama Information supplies the latest in independent market research for the life sciences and a full range of custom research services. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
3. Grammy Winner Marc Cohn to Perform for African AIDS Organization at Carolina HopeFest
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. UCLA Program Aims to Revolutionize Kidney Transplants
7. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
10. Allegheny General Hospital Performs First Liver Transplant
11. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/2/2017)... Calif. , Aug. 2, 2017 ... Continental Who,s Who as a Pinnacle Lifetime Professional ... the Key Account Manager at Turing Pharmaceuticals, AG. ... negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience as ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 19, 2017 , ... ... Thailand presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, ... Noppadon Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles and ... on resources available for individuals with hearing impairments and shares the latest innovations ...
(Date:8/18/2017)... WV (PRWEB) , ... August 18, 2017 , ... ... financial consulting services and asset protection assistance to communities in North-Central West Virginia, ... provide critical services to at-risk boys in the area. , The Chestnut Mountain ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... SAN DIEGO, CA & CARMEL, IN (PRWEB) , ... August 18, ... ... No. 3828 on its 36th annual list, the most prestigious ranking of the nation's ... ASH has been included in the exclusive Inc. 5000 ranking . This year’s ...
Breaking Medicine News(10 mins):